[en] We have previously shown that pirlindole and dehydropirlindole, two monoamine oxidase type-A inhibitors, protect cultured brain cells against iron-induced toxicity through a mechanism unrelated to monoamine oxidase type-A inhibition. The current study was performed to test whether the protective effect of pirlindole and dehydropirlindole could be extended to a nitric oxide (NO)-induced insult. A comparison with other monoamine oxidase inhibitors (brofaromine, moclobemide and deprenyl) and with trolox was made. In a first series of experiments, rat hippocampal or cortical cultured cells were exposed to a drug for 3 h, then 5 muM sodium nitroprusside, a NO donor, was added and the incubation was continued for 16 h. Cell survival assessment showed that pirlindole, dehydropirlindole and trolox significantly protected cultures against NO-induced toxicity in a concentration-dependent manner with respective EC50's of 7, 3 and 17 muM. Similarly, pirlindole, dehydropirlindole or trolox, at a concentration of 50 muM, significantly decreased both intracellular peroxide production and lipoperoxidation. Other drugs were ineffective. In a post-hoc treatment protocol (3- or 6-h pre-incubation in the presence of sodium nitroprusside, then addition of one of the above mentioned compounds), only pirlindole and dehydropirlindole significantly improved cell survival in a concentration-dependent manner with respective EC50'S of 9 and 4 muM. The maximal protection in terms of cell survival was 90% and 78% after 3 and 6 h, respectively. They also reduced the production of both lipoperoxides and endoperoxides. Our results show that pirlindole and dehydropirlindole protect neurons against NO-induced toxicity at pharmacologically relevant concentrations. Moreover, their protective effect is still apparent when they are applied after the start of the insult. Therefore, our preclinical study suggests a new strategy that may be efficient to reduce NO-induced damage in the central nervous system. (C) 2003 Elsevier Science B.V. All rights reserved.
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Boland, André ; Université de Liège - ULiège > Centre d'oncologie
Gérardy, Jean; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
Mossay, Danielle ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Pharmacologie
Altavilla D., Squadrito F., Campo G., Squadrito G., Arlotta M., Urna G., Sardella A., Quartarone C., Saitta A., Caputi A. The lazaroid, U-74389G, inhibits inducible nitric oxide synthase activity, reverses vascular failure and protects against endotoxin shock. Eur. J. Pharmacol. 369:1999;49-55.
Ashwal S., Tone B., Tian H., Cole D.J., Pearce W.J. Core and penumbral nitric oxide synthase activity during cerebral ischemia and reperfusion. Stroke. 29:1998;1037-1047.
Ay H., Ay I., Koroshetz W.J., Finklestein S.P. Potential usefulness of basic fibroblast growth factor as a treatment for stroke. Cerebrovasc. Dis. 9:1999;131-135.
Bastianetto S., Zheng W.H., Quirion R. Neuroprotective abilities of resveratrol and other red wine constituents against nitric oxide-related toxicity in cultured hippocampal neurons. Br. J. Pharmacol. 131:2000;711-720.
Blanc E.M., Kelly J.F., Mark R.J., Waeg G., Mattson M.P. 4-hydroxynonenal, an aldehydic product of lipid peroxidation, impairs signal transduction associated with the muscarinic acetylcholine and metabotropic glutamate receptors: possible action on Gαq-11. J. Neurochem. 69:1997;570-580.
Boland A., Delapierre D., Mossay D., Hans P., Dresse A. Propofol protects cultured brain cells from iron-induced death: comparison with trolox. Eur. J. Pharmacol. 404:2000;21-27.
Boland A., Delapierre D., Mossay D., Dresse A., Seutin V. Effect of intermittent and continuous exposure to electromagnetic fields on cultured hippocampal cells. Bioelectromagnetics. 23:2002;97-105.
Boland A., Gérardy J., Mossay D., Delapierre D., Seutin V. Pirlindole and dehydropirlindole protect rat cultured neuronal cells against oxidative stress-induced cell death through a mechanism unrelated to MAO-A inhibition. Br. J. Pharmacol. 135:2002;713-720.
Buisson A., Margaill I., Callebert J., Plotkine M., Boulu R.G. Mechanisms involved in the neuroprotective activity of a nitric oxide synthase inhibitor during focal cerebral ischemia. J. Neurochem. 61:1993;690-696.
Cuajungco M.P., Lees G.J. Nitric oxide generators produce accumulation of chelatable zinc in hippocampal neuronal perikarya. Brain Res. 799:1998;118-129.
Dawson T.M., Dawson V.L., Snyder S.H. Molecular mechanism of nitric oxide actions in the brain. Ann. N. Y. Acad. Sci. 738:1994;76-85.
Farinelli S.E., Park D.S., Greene L.A. Nitric oxide delays the death of trophic factor-deprived PC12 cells and sympathetic neurons by a cGMP-mediated mechanism. J. Neurosci. 16:1996;2325-2334.
Fici G.J., Althaus J.S., Hall E.D., Von Voigtlander P.F. Protective effects of tirilazad mesylate in a cellular model of peroxynitrite toxicity. Res. Commun. Mol. Pathol. Pharmacol. 91:1996;357-371.
Forman L.J., Liu P., Nagele R.G., Yin K., Wong Y.-K. Augmentation of nitric oxide, superoxide and peroxynitrite production during cerebral ischemia and reperfusion in the rat. Neurochem. Res. 23:1998;141-148.
Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 288:1980;373-376.
Garthwaite J. Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci. 14:1991;60-67.
Garthwaite G., Garthwaite J. Cyclic GMP and cell death in rat cerebellar slices. Neuroscience. 26:1988;321-326.
Haby C., Lisovoski F., Aunis D., Zwiller J. Stimulation of the cyclic GMP pathway by NO induces expression of the immediate early genes c-fos and jun B in PC12 cells. J. Neurochem. 62:1994;496-501.
Hagberg H., Gilland E., Diemer N.H., Andine P. Hypoxia-ischemia in the neonatal rat brain: histopathology after post-treatment with NMDA and non-NMDA receptor antagonists. Biol. Neonate. 66:1994;205-213.
Hölscher C. Nitric oxide, the enigmatic neuronal messenger: its role in synaptic plasticity. Trends Neurosci. 20:1997;298-303.
Holtz M.L., Craddock S.D., Pettigrew L.C. Rapid expression of neuronal and inducible nitric oxide synthases during post-ischemic reperfusion in rat brain. Brain Res. 898:2001;49-60.
Iadecola C. Bright and dark sides of nitric oxide in ischemic brain injury. Trends Neurosci. 20:1997;132-139.
Kearns S., Dawson R. Jr. Cytoprotective effect of taurine against hypochlorous acid toxicity to PC12 cells. Adv. Exp. Med. Biol. 483:2000;563-570.
Kohno K., Ohta S., Furuta S., Kohno Ka., Kumon Y., Sakaki S. Intraventricular administration of nitric oxide synthase inhibitors prevents delayed neuronal death in gerbil hippocampal CA1 neurons. Neurosci. Lett. 199:1995;65-68.
Kohno K., Higuchi T., Ohta S., Kumon Y., Sakaki S. Neuroprotective nitric oxide synthase inhibitor reduces intracellular calcium accumulation following transient global ischemia in the gerbil. Neurosci. Lett. 224:1997;17-20.
Leker R.R., Teichner A., Ovadia H., Keshet E., Reinherz E., Ben-Hur T. Expression of endothelial nitric oxide synthase in the ischemic penumbra: relationship to expression of neuronal nitric oxide synthase and vascular endothelial growth factor. Brain Res. 909:2001;1-7.
Lipton P. Ischemic cell death in brain neurons. Physiol. Rev. 79:1999;1431.
Lock E.A., Gyte A., Duffell S.J., Simpson M.G., Wyatt I. Neuroprotection afforded by MK-801 against L-2 chloroproprionic acid-induced cerebellar granule cell necrosis in the rat. Toxicology. 123:1997;41-51.
Maher P., Davis J.B. The role of monoamine metabolism in oxidative glutamate toxicity. J. Neurosci. 16:1996;6394-6401.
Mark R.J., Fuson K.S., Keane-Lazar K., May P.C. Fibroblast growth factor-8 protects cultured rat hippocampal neurons from oxidative insult. Brain Res. 830:1999;88-93.
Maruyama W., Naoi M. Neuroprotection by (-)-deprenyl and related compounds. Mech. Ageing Dev. 111:1999;189-200.
Maruyama W., Takahashi T., Naoi M. (-)-Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide. J. Neurochem. 70:1998;2510-2515.
Mattson M.P., Barger S.W., Begley J.G., Mark R.J. Calciun, free radicals, and excitotoxic neuronal death in primary cell culture. Methods Cell Biol. 46:1995;187-215.
Medvedev A., Gorkin V., Shvedov O., Fedotova I., Semiokhina A. Efficacy of pirlindole, a highly selective reversible inhibitor of monoamine oxidase type A, in the prevention of experimentally induced epileptic seizures. Drug Invest. 4:1992;501-507.
Moncada S., Palmer R.M., Higgs E.A. The discovery of nitric oxide as the endogenous nitrovasodilatator. Hypertension. 12:1988;365-372.
Mouithys-Mickalad A., Hans P., Deby-Dupont G., Hoebeke M., Deby C., Lamy M. Propofol reacts with peroxynitrite to form a phenoxyl radical: demonstration by electron spin resonance. Biochem. Biophys. Res. Comm. 249:1998;833-837.
Nanri K., Montécot C., Springhetti V., Seylaz J., Pinard E. The selective inhibitor of neuronal nitric oxide synthase, 7-nitroindazole, reduces the delayed neuronal damage due to forebrain ischemia in rats. Stroke. 29:1998;1248-1254.
Ohki K., Yoshida K., Hagiwara M., Harada T., Takamura M., Ohashi T., Matsuda H., Imaki J. Nitric oxide induces c-fos gene expression via cyclic AMP response element binding protein (CREB) phosphorylation in rat retinal pigment epithelium. Brain Res. 696:1995;140-144.
Pieper A.A., Verma A., Zhang J., Snyder S.H. Poly (ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol. Sci. 20:1999;171-181.
Pringle A.K., Iannoti F., Wilde G.J., Chad J.E., Seeley P.J. Neuroprotection by both NMDA and non-NMDA receptor antagonists in in vitro ischemia. Brain Res. 755:1997;36-46.
Rodrigo J., Alonso D., Fernandez A.P., Serrano J., Richart A., Lopez J.C., Santacana M., Martinez-Murillo R., Bentura M.L., Ghiglione M., Uttenthal L.O. Neuronal and inducible nitric oxide synthase expression and protein nitration in rat cerebellum after oxygen and glucose deprivation. Brain Res. 909:2001;20-45.
Sakakibara Y., Mitha A.P., Ogilvy C.S., Maynard K.I. Post-treatment with nicotinamide (vitamin B(3)) reduces the infarct volume following permanent focal cerebral ischemia in female Sprague-Dawley and Wistar rats. Neurosci. Lett. 281:2000;111-114.
Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., Woodbury P., Growdon J., Cotman C.W., Pfeiffer E., Schneider L.S., Thal C.W. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N. Engl. J. Med. 336:1997;1216-1222.
Stamler J.S., Singel D.J., Locaslzo J. Biochemistry of nitric oxide and its redox-activated forms. Science. 258:1992;1898-1902.
Szabo C., Dawson V.L. Role of poly(ADP-ribose) synthetase in inflammation and ischemia-reperfusion. Trends Pharmacol. Sci. 19:1998;287-298.
Tabuchi A., Oh E., Taoka A., Sakurai H., Tsuchiya T., Tsuda M. Rapid attenuation of AP-1 transcriptional factors associated with nitric oxide (NO)-mediated neuronal cell death. J. Biol. Chem. 271:1996;31061-31067.
Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328:1993;176-183.
Tortella F.C., Britton P., Williams A., Lu X.C., Newman A.H. Neuroprotection (focal ischemia) and neurotoxicity (electroencephalographic) studies in rats with AHN 649, a 3-amino analog of dextromethorphan and low-affinity N-methyl-D-aspartate antagonist. J. Pharmacol. Exp. Ther. 291:1999;399-408.
VanDyke K. The possible role of peroxynitrite in Alzheimer's disease: a simple hypothesis that could be tested more thoroughly. Med. Hypotheses. 48:1997;375-380.
Wei J., Quast M.J. Effect of nitric oxide synthase inhibitor on a hyperglycemic rat model of reversible focal ischemia: detection of excitatory amino acids release and hydroxyl radical formation. Brain Res. 791:1998;146-156.
Youdim M.B.H., Weinstock M. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R) aminoindan-5-YL)-ethyl methyl carbamate]. Cell. Mol. Neurobiol. 21:2001;555-573.
Youdim M.B.H., Ben-Shachar D., Eshel G., Finberg J.P.M., Riederer P. The neurotoxicity of iron and nitric oxide, relevance to the etiology of Parkinson's disease. Adv. Neurol. 60:1993;259-266.
Youdim M.B.H., Lavie L., Riederer P. Oxygen free radicals and neurodegeneretion in Parkinson's disease: a role for nitric oxide. Ann. N.Y. Acad. Sci. 738:1994;64-68.
Youdim M.B.H., Gross A., Finberg J.P.M. Rasagiline [N-propargyl-1R (+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br. J. Pharmacol. 132:2001;500-506.
Youdim M.B.H., Wadia A., Tatton W., Weinstock M. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann. N.Y. Acad. Sci. 939:2001;450-458.
Yuan S.Z., Runold M., Hagberg H., Bona E., Lagercrantz H. Hypoxic-ischaemic brain damage in immature rats: effects of adrenoceptor modulation. Eur. J. Paed. Neurol. 5:2001;29-35.